Key Points Novo Nordisk's Phase II trial found that semaglutide did not slow Alzheimer's progression. The setback comes as competition heats up in the obesity and diabetes drug market. 10 stocks we like better than Novo Nordisk › Shares of Novo Nordisk (NYSE: NVO) fell on Monday, finishing down 5.6%. The drop comes as the S&P 500 and the Nasdaq Composite gained 1.5% and 2.6%, respectively. The Danish drugmaker's stock slumped after the company announced that a Phase II trial had failed to show posi ...